Literature DB >> 30705848

Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients.

Waleed Kian1, Laila C Roisman1, Nir Peled1.   

Abstract

Entities:  

Year:  2018        PMID： 30705848      PMCID： PMC6328685          DOI： 10.21037/tlcr.2018.12.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  5 in total

Review 1.  Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

Authors:  Yi-Long Wu; Ross Andrew Soo; Giuseppe Locatelli; Uz Stammberger; Giorgio Scagliotti; Keunchil Park
Journal:  Cancer Treat Rev       Date:  2017-10-25       Impact factor: 12.111

Review 2.  Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation.

Authors:  Dianbo Yao; Chaoliu Dai; Songlin Peng
Journal:  Mol Cancer Res       Date:  2011-08-12       Impact factor: 5.852

3.  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Authors:  Seiji Yano; Wei Wang; Qi Li; Kunio Matsumoto; Haruko Sakurama; Takahiro Nakamura; Hirokazu Ogino; Soji Kakiuchi; Masaki Hanibuchi; Yasuhiko Nishioka; Hisanori Uehara; Tetsuya Mitsudomi; Yasushi Yatabe; Toshikazu Nakamura; Saburo Sone
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

Review 4.  Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy.

Authors:  Tatsuya Nagano; Motoko Tachihara; Yoshihiro Nishimura
Journal:  Cells       Date:  2018-11-15       Impact factor: 6.600

5.  Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.

Authors:  Seulki Kim; Tae Min Kim; Dong-Wan Kim; Soyeon Kim; Miso Kim; Yong-Oon Ahn; Bhumsuk Keam; Dae Seog Heo
Journal:  Cancer Res Treat       Date:  2018-10-10       Impact factor: 4.679
  5 in total
  3 in total

1.  Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.

Authors:  Theresa A Boyle; Farah K Khalil; Mari Mino-Kenudson; Gabriel L Sica; Andre L Moreira; Lynette M Sholl; Mirna Z Knight; Liping Zhang; James Saller; Marileila Varella-Garcia; Lynne D Berry; Heidi Chen; Kim E Ellison; Christopher J Rivard; Kelly Kugler; Ignacio I Wistuba; Junya Fujimoto; David J Kwiatkowski; Paul A Bunn; Mark G Kris; Eric B Haura; Fred R Hirsch
Journal:  Appl Immunohistochem Mol Morphol       Date:  2020-10

2.  The prognostic effect of TTF-1 expression in the Chinese population of patients with advanced lung adenocarcinomas.

Authors:  Xueying Li; Ling Yin; Yamei Zhao; Man He; Qi Qi; Yang Sun; Hongmei Li; Matthew Evison
Journal:  Transl Lung Cancer Res       Date:  2020-02

3.  CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.

Authors:  Juanni Li; Ayesha B Alvero; Sudhakar Nuti; Roslyn Tedja; Cai M Roberts; Mary Pitruzzello; Yimin Li; Qing Xiao; Sai Zhang; Yaqi Gan; Xiaoying Wu; Gil Mor; Gang Yin
Journal:  Oncogene       Date:  2020-03-23       Impact factor: 8.756
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.